Therapeutic compounds
The present invention relates to compositions comprising N,N-dimethyltryptamine, deuterated N,N-dimethyltryptamine and/or partially deuterated N,N-dimethyltryptamine. In particular, the present invention relates to compositions comprising a combination of N,N-dimethyltryptamine and 2% or more by weight of one or more deuterated N,N-dimethyltryptamine compound selected from α,α-dideutero-N,N-dimethyltryptamine and α,α,β,β-tetradeutero-N,N-dimethyltryptamine. Additional and alternative compositions of the present invention comprise a combination of N,N-dimethyltryptamine and 2% or more by weight of one or more partially deuterated N,N-dimethyltryptamine compound selected from α,β,β-trideutero-N,N-dimethyltryptamine, α,β-dideutero-N,N-dimethyltryptamine, and α-deutero-N,N-dimethyltryptamine. Methods of synthesising compositions of the present invention, and methods of use of presently described compositions in treating psychiatric or psychocognitive disorders, such as major depressive disorder, are also provided.
1. A deuterium-enriched N,N-dimethyltryptamine mixture consisting essentially of:
N,N-dimethyltryptamine, including pharmaceutically acceptable salts thereof; and
50% or more by weight in total of α-protio, α-deutero-N,N-dimethyltryptamine of the formula
including pharmaceutically acceptable salts thereof; and
α,α-dideutero-N,N-dimethyltryptamine of the formula
including pharmaceutically acceptable salts thereof;
wherein the mixture comprises 2% or more by weight of the α-protio, α-deutero-N,N-dimethyltryptamine, including pharmaceutically acceptable salts thereof; and
wherein the deuterium-enriched N,N-dimethyltryptamine mixture has a purity of greater than or equal to 99% by HPLC.
2. The deuterium-enriched N,N-dimethyltryptamine mixture of claim 1 , wherein the mixture comprises 2% or more by weight of the α,α-dideutero-N,N-dimethyltryptamine or a pharmaceutically acceptable salt thereof.
3. The deuterium-enriched N,N-dimethyltryptamine mixture of claim 1 , wherein the mixture comprises from 10% to 98% by weight of the α,α-dideutero-N,N-dimethyltryptamine, including pharmaceutically acceptable salts thereof.
4. The deuterium-enriched N,N-dimethyltryptamine mixture of claim 1 , wherein the mixture comprises up to 50% by weight of the α-protio, α-deutero-N,N-dimethyltryptamine, including pharmaceutically acceptable salts thereof.
5. The deuterium-enriched N,N-dimethyltryptamine mixture of claim 1 , wherein the pharmaceutically acceptable salt is a fumarate salt.
6. The deuterium-enriched N,N-dimethyltryptamine mixture of claim 1 , wherein the mixture comprises between 2% and 50% by weight of the α-protio, α-deutero-N,N-dimethyltryptamine, including pharmaceutically acceptable salts thereof.
7. The deuterium-enriched N,N-dimethyltryptamine mixture of claim 1 , wherein the mixture has a purity of greater than or equal to 99.9% by HPLC.
8. The deuterium-enriched N,N-dimethyltryptamine mixture of claim 1 , wherein the mixture comprises 60% or more by weight in total of the α-protio, α-deutero-N,N-dimethyltryptamine and the α,α-dideutero-N,N-dimethyltryptamine, including pharmaceutically acceptable salts thereof.
9. The deuterium-enriched N,N-dimethyltryptamine mixture of claim 1 , wherein the mixture comprises 75% or more by weight in total of the α-protio, α-deutero-N,N-dimethyltryptamine and the α,α-dideutero-N,N-dimethyltryptamine, including pharmaceutically acceptable salts thereof.